Aequus Pharmaceuticals Inc (V:AQS) — Market Cap & Net Worth
Market Cap & Net Worth: Aequus Pharmaceuticals Inc (AQS)
Aequus Pharmaceuticals Inc (V:AQS) has a market capitalization of $479.73K (CA$663.17K) as of September 17, 2026. Listed on the V stock exchange, this Canada-based company holds position #31080 globally and #1647 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Aequus Pharmaceuticals Inc's stock price CA$0.01 by its total outstanding shares 132634431 (132.63 Million). Also see Aequus Pharmaceuticals Inc asset portfolio for a full breakdown of the balance sheet.
Aequus Pharmaceuticals Inc Market Cap History: 2015 to 2026
Aequus Pharmaceuticals Inc's market capitalization history from 2015 to 2026. Data shows change from $59.49 Million to $479.73K (-36.46% CAGR). Also see cash efficiency ratio of Aequus Pharmaceuticals Inc for how efficiently the company converts equity into cash flow.
Aequus Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Aequus Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Aequus Pharmaceuticals Inc share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
1.64x
Aequus Pharmaceuticals Inc's market cap is 1.64 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $23.03 Million | $701.63K | -$4.81 Million | 32.82x | N/A |
| 2017 | $25.43 Million | $1.14 Million | -$3.88 Million | 22.31x | N/A |
| 2018 | $14.87 Million | $1.41 Million | -$2.80 Million | 10.55x | N/A |
| 2019 | $11.99 Million | $1.63 Million | -$3.11 Million | 7.35x | N/A |
| 2020 | $11.51 Million | $2.59 Million | -$1.05 Million | 4.44x | N/A |
| 2021 | $11.03 Million | $2.71 Million | -$1.81 Million | 4.06x | N/A |
| 2022 | $3.36 Million | $1.38 Million | -$3.21 Million | 2.43x | N/A |
| 2023 | $2.40 Million | $254.90K | -$2.96 Million | 9.41x | N/A |
| 2024 | $959.46K | $584.24K | -$2.18 Million | 1.64x | N/A |
Competitor Companies of AQS by Market Capitalization
Companies near Aequus Pharmaceuticals Inc in the global market cap rankings as of September 17, 2026. Review AQS intangible-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Aequus Pharmaceuticals Inc by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #631 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #636 globally with a market cap of $43.34 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #672 globally with a market cap of $40.69 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #631 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.00 |
| #636 | GALDERMA GROUP AG | NYSE:GALDY | $43.34 Billion | $37.18 |
| #672 | Haleon plc | NYSE:HLN | $40.69 Billion | $9.24 |
Aequus Pharmaceuticals Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Aequus Pharmaceuticals Inc's market cap moved from $59.49 Million to $ 479.73K, with a yearly change of -36.46%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CA$479.73K | 0.00% |
| 2025 | CA$479.73K | -50.00% |
| 2024 | CA$959.46K | -60.00% |
| 2023 | CA$2.40 Million | -28.57% |
| 2022 | CA$3.36 Million | -69.57% |
| 2021 | CA$11.03 Million | -4.17% |
| 2020 | CA$11.51 Million | -4.00% |
| 2019 | CA$11.99 Million | -19.35% |
| 2018 | CA$14.87 Million | -41.51% |
| 2017 | CA$25.43 Million | +10.42% |
| 2016 | CA$23.03 Million | -61.29% |
| 2015 | CA$59.49 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Aequus Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $479.73K USD |
| MoneyControl | $479.73K USD |
| MarketWatch | $479.73K USD |
| marketcap.company | $479.73K USD |
| Reuters | $479.73K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Aequus Pharmaceuticals Inc
Aequus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. The company offers ZIMED PF, a preservative-free bimatoprost prescription drug for the for the reduction of elevated interocular pressure in patients with open angle glaucoma or ocular hypertension. It also develops REV-0100, which is in pre-clinical trial for the treatment of stargardt disease. Aequus Pharmaceu… Read more